Medicamen Organics Limited (NSE:MEDIORG)

Market Cap	321.17M -53.8%
Revenue (ttm)	394.30M +28.0%
Net Income	45.74M +79.2%
EPS	3.84 +39.1%
Shares Out	11.70M
PE Ratio	7.15
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	42,000
Average Volume	14,100
Open	29.30
Previous Close	27.45
Day's Range	27.45 - 30.25
52-Week Range	19.60 - 49.70
Beta	n/a
RSI	56.55
Earnings Date	Feb 13, 2026

About Medicamen Organics

Medicamen Organics Limited develops, manufactures, and distributes a range of pharmaceutical dosage. The company offers anti-bacterial, anti-diarrheal, anti-fungal, anti-malarial, anti-diabetic, dental cure, proton pump inhibitor, anti-protozoal, anti-histamine, anti-hypertensive, anti-lipidemic, anti-parasitic, multivitamin, multimineral, and non-steroidal anti-inflammatory drugs in the form of tablets, capsules, oral liquids, ointments, gels, syrups, suspensions, and dry powders. It also provides skincare, haircare, and cosmetic products unde...

• Industry: Pharmaceutical Preparations
• Founded: 1995
• Employees: 114
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: MEDIORG

Financial Performance

In fiscal year 2025, Medicamen Organics's revenue was 381.88 million, an increase of 51.11% compared to the previous year's 252.72 million. Earnings were 40.47 million, an increase of 54.22%.